Another NASH Failure: Gilead’s Hits Keep Coming

 
• By Mary Jo Laffler

The failure of the STELLAR-3 trial of selonsertib had been widely anticipated following the failure in a sicker population in STELLAR-4.

Bright, blue green wave breaks on body boarder and sends red board flying at the Wedge, Newport Beach. - Image
Another wave of disappointment for Gilead

More from Clinical Trials

More from R&D